Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances

Cartesian Therapeutics (RNAC) Long-Term Debt Issuances (2020)

Cartesian Therapeutics (RNAC) has disclosed Long-Term Debt Issuances for 1 consecutive years, with -$102000.0 as the latest value for Q4 2020.

For Q4 2020, Long-Term Debt Issuances changed N/A year-over-year to -$102000.0; the TTM value through Dec 2021 reached -$102000.0, changed 0.0%, while the annual FY2020 figure was $24.7 million, N/A changed from the prior year.
Long-Term Debt Issuances hit -$102000.0 in Q4 2020 for Cartesian Therapeutics.
Across five years, Long-Term Debt Issuances topped out at -$102000.0 in Q4 2020 and bottomed at -$102000.0 in Q4 2020.